Xenon Pharmaceuticals Inc. (XENE) reports insider transaction.
- Kelly Thomas Patrick, CFO, received 7,500 common shares on 10/15/2026.
- The shares were part of a restricted share unit (RSU) award granted on 10/15/2025.
Thomas Patrick Kelly, reporting
XENE
Xenon Pharmaceuticals Inc. SEC filings
Every EDGAR filing for Xenon Pharmaceuticals Inc. (XENE), newest first, with AI summaries and stories.
- Ticker
- XENE
- CIK
- 1582313
- Latest filing
- 2d
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 9)
Insider activity
- CFO bought $560K
- PRESIDENT & CEO bought $1.1M
Also: 1 grant or exercise.
Filings
4Xenon Pharmaceuticals Inc.XENELIVE 4Xenon Pharmaceuticals Inc.XENELIVE 2 insider filings
Ian Mortimer, insider filing for XENE
Show all 2
- 4Insider filing for XENE
- 4Insider filing for XENE
Ian Mortimer
4Xenon Pharmaceuticals Inc.XENELIVE Dawn Svoronos, insider filing for XENE
Dawn Svoronos, reporting
4Xenon Pharmaceuticals Inc.XENELIVE Christopher John Kenney, insider filing for XENE
Christopher John Kenney, reporting
144Xenon Pharmaceuticals Inc.XENELIVE Christopher John Kenney, planned sale of XENE shares
Christopher John Kenney, reporting
4Xenon Pharmaceuticals Inc.XENELIVE Steven Gannon, insider filing for XENE
Steven Gannon, reporting
144Xenon Pharmaceuticals Inc.XENELIVE Steven Gannon, planned sale of XENE shares
Steven Gannon, reporting
SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by WELLINGTON MANAGEMENT GROUP LLP (amended)
WELLINGTON MANAGEMENT GROUP LLP, filed by
SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
10-QXenon Pharmaceuticals Inc.XENELIVE 8-KXenon Pharmaceuticals Inc.XENELIVE SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
4Xenon Pharmaceuticals Inc.XENELIVE 2 insider filings
Gary Patou, insider filing for XENE
Show all 2
- 4Insider filing for XENE
- 4Insider filing for XENE
Gary Patou, reporting
144Xenon Pharmaceuticals Inc.XENELIVE 2 Form 144 notices
Gillian Cannon, planned sale of XENE shares
Show all 2
- 144Planned insider sale of XENE shares
- 144Planned insider sale of XENE shares
Gillian Cannon, reporting
4Xenon Pharmaceuticals Inc.XENELIVE 7 insider filings
Gary Patou, insider filing for XENE
Show all 7
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
Gary Patou, reporting
S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8 POSXenon Pharmaceuticals Inc.XENELIVE S-8Xenon Pharmaceuticals Inc.XENELIVE 8-KXenon Pharmaceuticals Inc.XENELIVE SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by JANUS HENDERSON GROUP PLC (amended)
JANUS HENDERSON GROUP PLC, filed by
SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by Avoro Capital Advisors LLC (amended)
Avoro Capital Advisors LLC, filed by
SCHEDULE 13G/AXenon Pharmaceuticals Inc.XENELIVE Ownership stake disclosure by DRIEHAUS CAPITAL MANAGEMENT LLC (amended)
DRIEHAUS CAPITAL MANAGEMENT LLC, filed by
4Xenon Pharmaceuticals Inc.XENELIVE Steven Gannon, insider filing for XENE
Steven Gannon, reporting
10-QXenon Pharmaceuticals Inc.XENELIVE 8-KXenon Pharmaceuticals Inc.XENELIVE ARSXenon Pharmaceuticals Inc.XENELIVE DEFA14AXenon Pharmaceuticals Inc.XENELIVE DEF 14AXenon Pharmaceuticals Inc.XENELIVE S-8Xenon Pharmaceuticals Inc.XENELIVE 8-KXenon Pharmaceuticals Inc.XENELIVE 4Xenon Pharmaceuticals Inc.XENELIVE 3 insider filings
Christopher John Kenney, insider filing for XENE
Show all 3
- 4Insider filing for XENE
- 4Insider filing for XENE
- 4Insider filing for XENE
Christopher John Kenney, reporting